Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
11:21am, Thursday, 26'th Dec 2024
AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca
AZN INVESTOR DEADLINE: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
06:55am, Thursday, 26'th Dec 2024
SAN DIEGO , Dec. 26, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between Fe
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption – Hagens Berman
04:44pm, Tuesday, 24'th Dec 2024
SAN FRANCISCO, Dec. 24, 2024 (GLOBE NEWSWIRE) -- AstraZeneca, the British-Swedish pharmaceutical giant, is facing a securities class action lawsuit in the U.S. alleging the company misled investors ab
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
04:00pm, Tuesday, 24'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advise
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN
01:05pm, Tuesday, 24'th Dec 2024
NEW YORK , Dec. 24, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca P
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC (AZN)
12:07pm, Tuesday, 24'th Dec 2024
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of Ca
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
09:30am, Tuesday, 24'th Dec 2024
- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction -
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca
AstraZeneca pulls lung cancer drug application in EU
03:49am, Tuesday, 24'th Dec 2024
AstraZeneca PLC (LSE:AZN) has pulled a marketing authorisation application for its key lung cancer drug in the European Union. FTSE 100-listed AstraZeneca noted on Tuesday that it had voluntarily with
AstraZeneca withdraws application for lung cancer drug in EU
03:09am, Tuesday, 24'th Dec 2024
AstraZeneca said on Tuesday it had voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision drug for treatment of a type of lung c
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn
02:00am, Tuesday, 24'th Dec 2024
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab der
Investors can contact the law firm at no cost to learn more about recovering their losses
